The study involves people with asthma, a condition that makes the airways narrow and can cause wheezing, coughing, and shortness of breath. The medication being tested is an inhaled steroid called beclometasone dipropionate, which is delivered through a press‑urized metered‑dose inhaler (pMDI). The inhaler used in the trial is identified as CHF 718 pMDI HFA-152a and is compared with a similar device that uses a different propellant. Both inhalers are used together with a Volumatic® spacer, a plastic tube that helps the medicine reach the lungs more effectively. The drug is broken down in the body to an active form called beclometasone 17-monoproprionate, which also contributes to the treatment effect.
The purpose of the study is to evaluate how much of the medication reaches the lungs and how much enters the bloodstream. In this phase I trial, healthy adult volunteers receive a single dose of one inhaler, then after a short break they receive a dose of the other inhaler in a “crossover” design, meaning each participant tries both devices. Blood samples are taken after each dose to measure the drug and its active breakdown product, and the timing of these samples follows a simple schedule. The study does not involve any long‑term treatment, and participants are monitored only for a short period after each inhalation.
Belgium 
